Association of Elevated E6 Oncoprotein With Grade of Cervical Neoplasia Using PDZ Interaction-Mediated Precipitation of E6

Objective. To determine the expression of human papillomavirus (HPV) type 16 E6 oncoprotein in cervical specimens of women with and without cervical intraepithelial neoplasia (CIN). Materials and Methods. Cervical specimens from 2,530 unscreened women aged 30 to 54 years from Shanxi, China, were obtained. All women were assessed by liquid-based cytology, high-risk HPV DNA tests, and colposcopy with directed biopsy and endocervical curettage as necessary. Women with abnormal cytologic results or positive HPV DNA results were recalled for colposcopy, 4-quadrant cervical biopsies, and endocervical curettage. Women with biopsy-proven CIN and cancer and a convenience sample of HC2-positive, disease-negative women were tested for the presence of HPV-16 infection via HPV-16 E6 DNA-specific polymerase chain reaction. A PDZ interaction-mediated E6 oncoprotein precipitation method followed by E6-specific Western blot was performed on specimens from women with HPV-16 infections. Associations between elevated expression of E6 oncoprotein and CIN 2 and 3 were determined using logistic regression and a reference category of CIN 1 and disease-negative. Results. A significant trend for the detection of HPV-16 E6 oncoprotein in specimen of women with proven HPV-16 infection was determined: 0% (0/12), 12.5% (1/8), 36.4% (4/11), and 42.9% (3/7) of those with negative findings, CIN 1, 2, and 3, respectively (p = .01). Compared with the category combining negative findings and CIN 1, detection of E6 oncoprotein was associated with CIN 2 (odds ratio = 10.9, p = .05) and CIN 3 (odds ratio = 14.3, p = .04). Conclusions. There is a significant association between elevated expression of E6 oncoprotein and grade of CIN. This finding seems consistent with the role played by E6 oncoprotein in carcinogenesis.

[1]  Feng Chen,et al.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. , 2008, The Lancet. Oncology.

[2]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[3]  C. Wheeler,et al.  New technologies in cervical cancer screening. , 2008, Vaccine.

[4]  Francisco A. R. Garcia,et al.  A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer , 2007, Clinical Cancer Research.

[5]  P. Lambert,et al.  The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. , 2007, Cancer research.

[6]  E. Yim,et al.  Biomarkers in Cervical Cancer , 2006, Biomarker insights.

[7]  M. Schiffman,et al.  Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.

[8]  H. Skomedal,et al.  Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV‐proofer and consensus PCR: A 2‐year follow‐up of women with ASCUS or LSIL pap smear , 2005, International journal of cancer.

[9]  Choongho Lee,et al.  Role of the PDZ Domain-Binding Motif of the Oncoprotein E6 in the Pathogenesis of Human Papillomavirus Type 31 , 2004, Journal of Virology.

[10]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[11]  Karl Münger,et al.  Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins , 2004, International journal of cancer.

[12]  H. Skomedal,et al.  Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones , 2004, British Journal of Cancer.

[13]  Minh N. H. Nguyen,et al.  The PDZ Ligand Domain of the Human Papillomavirus Type 16 E6 Protein Is Required for E6's Induction of Epithelial Hyperplasia In Vivo , 2003, Journal of Virology.

[14]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[15]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[16]  K. Münger The role of human papillomaviruses in human cancers. , 2002, Frontiers in bioscience : a journal and virtual library.

[17]  Miranda Thomas,et al.  HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation , 2001, Oncogene.

[18]  M. von Knebel Doeberitz,et al.  Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. , 1999, Cancer research.

[19]  A. Miller,et al.  Natural history of dysplasia of the uterine cervix. , 1999, Journal of the National Cancer Institute.

[20]  Lydia P. Howell,et al.  NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[21]  M. Nair,et al.  High-Risk Human Papillomavirus Infection and E6 Protein Expression in Lesions of the Uterine Cervix , 1998, Pathobiology.

[22]  M Fujita,et al.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Ostör Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[24]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.